Last reviewed · How we verify
Liquid 13-Cis Retinoic Acid
At a glance
| Generic name | Liquid 13-Cis Retinoic Acid |
|---|---|
| Also known as | Isotretinoin |
| Sponsor | Nova Laboratories Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Oral Liquid 13-cis-retinoic Acid (13-CRA) (PHASE1, PHASE2)
- Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liquid 13-Cis Retinoic Acid CI brief — competitive landscape report
- Liquid 13-Cis Retinoic Acid updates RSS · CI watch RSS
- Nova Laboratories Limited portfolio CI